JP2005502322A - 非天然アミノ酸のインビボ組込み - Google Patents

非天然アミノ酸のインビボ組込み Download PDF

Info

Publication number
JP2005502322A
JP2005502322A JP2002583449A JP2002583449A JP2005502322A JP 2005502322 A JP2005502322 A JP 2005502322A JP 2002583449 A JP2002583449 A JP 2002583449A JP 2002583449 A JP2002583449 A JP 2002583449A JP 2005502322 A JP2005502322 A JP 2005502322A
Authority
JP
Japan
Prior art keywords
protein
amino acids
receptor
amino acid
unnatural amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002583449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502322A5 (enExample
Inventor
ペーター・シュルツ
レイ・ワン
ジョン・クリストファー・アンダーソン
ジェイソン・ダブリュー．・チン
デイヴッド・アール．・リウ
トーマス・ジェー．・マグライリー
エリック・エル．・メッゲルス
ライアン・アーロン・メール
ミロ・パストラナック
ステファン・ウィリアム・サントロ
ツィーウェン・チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of JP2005502322A publication Critical patent/JP2005502322A/ja
Publication of JP2005502322A5 publication Critical patent/JP2005502322A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2002583449A 2001-04-19 2002-04-19 非天然アミノ酸のインビボ組込み Pending JP2005502322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28503001P 2001-04-19 2001-04-19
US35551402P 2002-02-06 2002-02-06
PCT/US2002/012465 WO2002085923A2 (en) 2001-04-19 2002-04-19 In vivo incorporation of unnatural amino acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008285996A Division JP2009132704A (ja) 2001-04-19 2008-11-06 非天然アミノ酸のインビボ組込み

Publications (2)

Publication Number Publication Date
JP2005502322A true JP2005502322A (ja) 2005-01-27
JP2005502322A5 JP2005502322A5 (enExample) 2009-01-08

Family

ID=26962950

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2002583449A Pending JP2005502322A (ja) 2001-04-19 2002-04-19 非天然アミノ酸のインビボ組込み
JP2002583590A Pending JP2004537984A (ja) 2001-04-19 2002-04-19 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2008285996A Pending JP2009132704A (ja) 2001-04-19 2008-11-06 非天然アミノ酸のインビボ組込み
JP2008285997A Pending JP2009077731A (ja) 2001-04-19 2008-11-06 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2010211248A Expired - Lifetime JP5766925B2 (ja) 2001-04-19 2010-09-21 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2013156012A Expired - Lifetime JP6239888B2 (ja) 2001-04-19 2013-07-26 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2016021701A Expired - Lifetime JP6294368B2 (ja) 2001-04-19 2016-02-08 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2002583590A Pending JP2004537984A (ja) 2001-04-19 2002-04-19 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2008285996A Pending JP2009132704A (ja) 2001-04-19 2008-11-06 非天然アミノ酸のインビボ組込み
JP2008285997A Pending JP2009077731A (ja) 2001-04-19 2008-11-06 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2010211248A Expired - Lifetime JP5766925B2 (ja) 2001-04-19 2010-09-21 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2013156012A Expired - Lifetime JP6239888B2 (ja) 2001-04-19 2013-07-26 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2016021701A Expired - Lifetime JP6294368B2 (ja) 2001-04-19 2016-02-08 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物

Country Status (11)

Country Link
US (19) US7045337B2 (enExample)
EP (5) EP1456360B1 (enExample)
JP (7) JP2005502322A (enExample)
AU (2) AU2002256292C1 (enExample)
CA (2) CA2443757C (enExample)
DK (4) DK1490483T3 (enExample)
ES (1) ES2464532T3 (enExample)
HK (1) HK1203558A1 (enExample)
IL (7) IL158418A0 (enExample)
MX (2) MXPA03009566A (enExample)
WO (2) WO2002086075A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009132704A (ja) * 2001-04-19 2009-06-18 Scripps Res Inst:The 非天然アミノ酸のインビボ組込み
JP2010502218A (ja) * 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
JP2010502222A (ja) * 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
JP2010504096A (ja) * 2006-09-21 2010-02-12 ザ スクリップス リサーチ インスティテュート 真正細菌における選択的に硫酸化された蛋白質の遺伝的にプログラムされた発現
JP2011502507A (ja) * 2007-11-02 2011-01-27 ザ スクリプス リサーチ インスティチュート 非天然アミノ酸を含有する蛋白質を使用する指向的進化
JP2011527886A (ja) * 2007-12-11 2011-11-10 ザ スクリプス リサーチ インスティチュート メタノール資化性酵母ピキア・パストリスにおけるインビボ非天然アミノ酸発現
WO2011158895A1 (ja) * 2010-06-16 2011-12-22 独立行政法人理化学研究所 非天然タンパク質製造用の組換え細菌の作製方法、及びその利用
KR101568336B1 (ko) 2013-07-02 2015-11-12 서강대학교산학협력단 목적 단백질의 돌연변이체를 생성하는 세포, 상기 세포의 제조 방법, 및 상기 세포를 이용한 목적 단백질의 돌연변이체의 제조 방법
JP2022554396A (ja) * 2019-11-05 2022-12-28 ニトロ バイオサイエンシーズ， インコーポレイテッド パラ－ニトロ－ｌ－フェニルアラニンの生合成

Families Citing this family (420)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964859B2 (en) 2001-10-16 2005-11-15 Massachusetts Institute Of Technology Suppressor tRNA system
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US20040038273A1 (en) * 2002-06-17 2004-02-26 Whitehead Institute For Biomedical Research Bifunctional tRNA for in vitro selection
AU2003252153A1 (en) * 2002-07-25 2004-02-16 Mds Proteomics Inc. Improved systems and methods for analysis of protein post-translational modification
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7897381B2 (en) * 2002-08-07 2011-03-01 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
ATE526414T1 (de) 2002-10-16 2011-10-15 Scripps Research Inst Ortsspezifische einbindung von ketoaminosäuren in proteine
KR20050073559A (ko) * 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
US7642085B2 (en) 2002-12-22 2010-01-05 The Scripps Research Institute Protein arrays
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006180701A (ja) * 2003-02-10 2006-07-13 Institute Of Physical & Chemical Research チロシルｔＲＮＡ合成酵素の変異体及びその作製方法
KR101171397B1 (ko) * 2003-04-17 2012-08-07 더 스크립스 리서치 인스티튜트 진핵 유전자 코드의 확장
AU2013201487B2 (en) * 2003-04-17 2014-09-18 The Scripps Research Institute Expanding the eukaryotic genetic code
WO2004110964A2 (en) * 2003-06-16 2004-12-23 Nuevolution A/S Encoded molecules by translation (emt)
CA2527877A1 (en) * 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
ATE386133T1 (de) * 2003-07-07 2008-03-15 Scripps Research Inst Zusammensetzungen der orthogonalen lysyl-trna und aminoacyl-trna synthetase paaren und ihre verwendungen
WO2005007870A2 (en) * 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
US7527943B2 (en) 2003-07-07 2009-05-05 The Scripps Research Institute Compositions of orthogonal glutamyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
ATE447611T1 (de) * 2003-08-18 2009-11-15 Univ California Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
BRPI0415308A (pt) * 2003-10-14 2006-12-05 Scripps Research Inst incorporação especìfica de local de aminoácidos redox ativos em proteìnas
CA2549263A1 (en) * 2003-12-12 2005-08-11 Conjugon, Inc. Systems for tightly regulated gene expression
US7741071B2 (en) * 2003-12-18 2010-06-22 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
AU2005222788A1 (en) * 2004-02-27 2005-09-29 President And Fellows Of Harvard College Polynucleotide synthesis
FR2868081A1 (fr) * 2004-03-23 2005-09-30 Libragen Sa Methode d'identification de famille de voie metabolique par selection positive
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
EP1757686A4 (en) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd INDUCER OF CELL DEATH
US20050287639A1 (en) * 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
US7399619B2 (en) * 2004-05-25 2008-07-15 The Scripps Research Institute Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for structure determination
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
ZA200609926B (en) * 2004-06-18 2009-02-25 Ambrx Inc Novel antigen-binding polypeptides and their uses
WO2006009901A2 (en) * 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
CN101044164A (zh) 2004-07-20 2007-09-26 健泰科生物技术公司 血管生成素样4蛋白抑制剂，组合，以及其用途
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
BRPI0515547A (pt) * 2004-09-21 2008-07-29 Scripps Research Inst incorporação in vivo de aminoácidos alquinil em proteìnas em eubacterias
US20060110784A1 (en) * 2004-09-22 2006-05-25 The Scripps Research Institute Site-specific labeling of proteins for NMR studies
US20070122817A1 (en) * 2005-02-28 2007-05-31 George Church Methods for assembly of high fidelity synthetic polynucleotides
WO2006044956A1 (en) * 2004-10-18 2006-04-27 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
WO2006045116A2 (en) * 2004-10-20 2006-04-27 The Scripps Research Institute In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
AU2011204773B2 (en) * 2004-10-27 2012-02-02 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
WO2006110182A2 (en) * 2004-10-27 2006-10-19 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US20060134748A1 (en) * 2004-11-20 2006-06-22 Rajbhandary Uttam Orthogonal suppressor tRNAs and aminoacyl-tRNA synthetases and uses thereof
WO2006054807A1 (ja) * 2004-11-22 2006-05-26 Gifu University ミトコンドリア蛋白質を用いる、非天然アミノ酸を蛋白質に部位特異的に導入する方法及びtRNAの効率的調製方法
AU2005322019B2 (en) * 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2013205030B2 (en) * 2004-12-22 2016-05-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0518661A2 (pt) * 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7723069B2 (en) * 2005-04-05 2010-05-25 Yale University Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-tRNA synthetase
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006122224A1 (en) 2005-05-11 2006-11-16 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in pseudomonas aeruginosa
MX2007015058A (es) * 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
EP1891092A4 (en) * 2005-06-03 2011-12-21 Ambrx Inc INSTALLATION OF NATURALLY CODED AMINO ACIDS IN PROTEINS
JP5068167B2 (ja) * 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
WO2007005053A1 (en) * 2005-06-30 2007-01-11 Codon Devices, Inc. Hierarchical assembly methods for genome engineering
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
CA2782619A1 (en) * 2005-07-15 2007-01-25 Medical Research Council Compositions and methods relating to orthogonal ribosome mrna pairs
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN103103238B (zh) * 2005-08-18 2016-08-10 Ambrx公司 一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
BRPI0617191A2 (pt) * 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos
CN106443006A (zh) 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2633524A1 (en) 2005-12-22 2007-07-05 Pacific Biosciences Of California, Inc. Polymerases for nucleotide analogue incorporation
CN102702105A (zh) * 2005-12-30 2012-10-03 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US20090093405A1 (en) * 2006-01-19 2009-04-09 Ambrx, Inc. Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity
US20070178554A1 (en) * 2006-02-01 2007-08-02 Nima Shiva Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins
US20090081669A1 (en) * 2006-02-01 2009-03-26 Encode Bio, Inc. Fluorescent Assays Using Orthogonal tRNA - Aminoacyl Synthetase Pairs
US7776535B2 (en) * 2006-02-06 2010-08-17 Franklin And Marshall College Site-specific incorporation of fluorinated amino acids into proteins
EP1999259B1 (en) 2006-03-03 2014-06-25 California Institute of Technology Site-specific incorporation of amino acids into molecules
EP1991680B1 (en) 2006-03-09 2013-08-21 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
US7790847B2 (en) * 2006-03-16 2010-09-07 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
CA2653748A1 (en) 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
CA2652894A1 (en) 2006-05-23 2007-12-06 The Scripps Research Institute Genetically encoded fluorescent coumarin amino acids
JP2009539805A (ja) * 2006-06-09 2009-11-19 ノバルティス アクチエンゲゼルシャフト 安定化されたインスリン様増殖因子ポリペプチド
ATE533846T1 (de) * 2006-06-28 2011-12-15 Riken Seprs-mutante und verfahren zur stellengerichteten einführung von phosphoserin in protein unter verwendung davon
ES2415635T3 (es) * 2006-06-29 2013-07-26 The Board Of Trustees Of The Leland Stanford Junior University Síntesis acelular de proteínas que contienen aminoácidos no naturales
CN101517075A (zh) * 2006-07-13 2009-08-26 中外制药株式会社 细胞死亡诱导剂
AU2013202770B2 (en) * 2006-09-08 2015-08-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
CA2662755C (en) 2006-09-08 2017-04-04 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
MX2009002524A (es) * 2006-09-08 2009-06-22 Ambrx Inc Incorporacion especifica de sitio de aminoacidos no naturales por celulas de vertebrados.
AU2012203737B2 (en) * 2006-09-08 2014-06-19 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
RU2009112104A (ru) 2006-10-18 2010-11-27 Зе Скрипс Ресеч Инститьют (Us) Генетическое встраивание не встречающихся в природе аминокислот в белки клеток млекопитающих
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
EP1936340A1 (en) * 2006-12-21 2008-06-25 Koninklijke Philips Electronics N.V. Sub wavelength aperture
EP2112928A4 (en) * 2007-02-22 2014-01-08 Univ Utah Res Found SYNTHESIS OF NOVEL XYLOSIDES AND ITS POSSIBLE USES
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EP2155890A4 (en) * 2007-04-13 2010-04-21 Salk Inst For Biological Studi METHOD FOR THE GENETIC CODING OF NON-NATURAL AMINO ACIDS IN EUKARYONTIC CELLS USING ORTHOGONAL TRNA / SYNTHETASE PAIRS
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8293685B2 (en) * 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
AU2008310912A1 (en) * 2007-10-08 2009-04-16 Synthetic Genomics, Inc. System and method for producing synthetic microorganisms capable of translating proteins containing non-standard amino acids
MX2010004464A (es) 2007-10-25 2010-06-07 Scripps Research Inst Incorporacion genetica de 3-aminotirosina a reductasas.
US20090148887A1 (en) * 2007-11-02 2009-06-11 The Scripps Research Institute Genetically encoded boronate amino acid
JP5764329B2 (ja) 2007-11-02 2015-08-19 ノバルティス アーゲー 低比重リポタンパク質受容体関連タンパク質６（ｌｒｐ６）を調節するための分子および方法
WO2009064416A2 (en) * 2007-11-15 2009-05-22 The Scripps Research Institute Genetic incorporation of an alpha-hydroxy acid into proteins to generate ester backbone linkages at defined sites
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
JP5563990B2 (ja) 2008-01-03 2014-07-30 ヴェレニウム コーポレイション トランスフェラーゼおよびオキシドレダクターゼ、それらをコードする核酸並びにそれらを製造および使用する方法
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US8318172B2 (en) * 2008-02-08 2012-11-27 The Scripps Research Institute Breaking immunological tolerance with a genetically encoded unnatural amino acid
WO2009117622A2 (en) * 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
WO2009117726A2 (en) * 2008-03-21 2009-09-24 The Regents Of The University Of California High-sensitive fluorescent energy transfer assay using fluorescent amino acids and fluoresent proteins
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP2271751B1 (en) 2008-03-31 2015-07-22 Pacific Biosciences of California, Inc. Generation of modified polymerases for improved accuracy in single molecule sequencing
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
BRPI0915419A2 (pt) 2008-06-20 2015-11-03 Massachusetts Inst Technology imunoglobulinas com agregação reduzida
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
RU2016108598A (ru) 2008-06-30 2018-11-23 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010022171A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Peptidic pth receptor agonists
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
JP5542832B2 (ja) 2008-10-24 2014-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US8609383B2 (en) 2008-12-10 2013-12-17 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
US20090197339A1 (en) * 2008-12-10 2009-08-06 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN102300580A (zh) * 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120004185A1 (en) 2009-02-27 2012-01-05 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
EP2414513B1 (en) * 2009-03-31 2015-10-28 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2010132341A2 (en) 2009-05-11 2010-11-18 Pfenex, Inc. Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein
WO2010141902A2 (en) 2009-06-04 2010-12-09 Novartis Ag METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
US20110054019A1 (en) * 2009-09-01 2011-03-03 Pedro Anastacio Serrano-Ojeda Cancer Starvation Therapy
US10292956B2 (en) 2009-09-01 2019-05-21 Serbig Pharmaceutics Corp. Cancer starvation therapy
EP2311947A1 (en) * 2009-10-14 2011-04-20 Ludwig-Maximilians-Universität München Protein synthesis via click chemistry
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN102640001A (zh) 2009-11-05 2012-08-15 诺瓦提斯公司 预测纤维化进展的生物标记物
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
US9051593B2 (en) 2009-12-21 2015-06-09 Trustees Of Dartmouth College Recombinant prokaryotes and use thereof for production of O-glycosylated proteins
US8637456B2 (en) 2010-01-27 2014-01-28 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
US8674064B2 (en) * 2010-03-03 2014-03-18 Onkologix Ltd Immunogenic compositions against human progastrin peptides
US8464858B2 (en) 2010-03-12 2013-06-18 Cabin Creek Inc. Conveyor belt scraper and system for the same
WO2011119771A2 (en) * 2010-03-23 2011-09-29 The Salk Institute For Biological Studies Methods and compositions for detecting protein modifications
CN103118692A (zh) 2010-04-26 2013-05-22 Atyr医药公司 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
CA2797259C (en) 2010-04-27 2020-09-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
CN103118693B (zh) 2010-04-29 2017-05-03 Atyr 医药公司 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
EP2566516B1 (en) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2798301C (en) 2010-05-04 2020-09-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CN103068842B (zh) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
NZ603811A (en) * 2010-07-12 2015-03-27 Atyr Pharma Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
EA030418B1 (ru) 2010-07-12 2018-08-31 ЭйТИР ФАРМА, ИНК. ТЕРАПЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ, ПОЛИПЕПТИД АМИНОАЦИЛ-тРНК-СИНТЕТАЗЫ (AARS)
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
KR101963460B1 (ko) 2010-08-17 2019-03-28 암브룩스, 인코포레이티드 변형된 릴랙신 폴리펩타이드 및 그것의 용도
US9029506B2 (en) 2010-08-25 2015-05-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN103118696B (zh) * 2010-10-06 2020-02-14 Atyr 医药公司 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
US9090928B2 (en) 2010-10-07 2015-07-28 Yale University Site-specific incorporation of phosphoserine into proteins in Escherichia coli
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
EP2670767B1 (en) 2011-02-03 2017-12-20 European Molecular Biology Laboratory Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof
AU2012230899A1 (en) 2011-03-21 2013-10-10 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
EP2694083A2 (en) * 2011-04-01 2014-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
DK2714684T3 (en) 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
US11788111B2 (en) 2011-07-11 2023-10-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US9464288B2 (en) 2011-07-11 2016-10-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
CN102888387B (zh) * 2011-07-21 2015-03-18 中国科学院生物物理研究所 3-氯代酪氨酸翻译系统及其应用
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN102925427B (zh) * 2011-08-08 2014-01-22 中国科学院生物物理研究所 丙烯酰赖氨酸翻译系统及其应用
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
EP2813512B1 (en) 2011-12-28 2021-03-31 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
CN104220461A (zh) 2011-12-29 2014-12-17 Atyr医药公司 天冬氨酰-tRNA合成酶-FC缀合物
US9395358B2 (en) 2012-02-05 2016-07-19 Biodesy, Inc. Methods for detecting allosteric modulators of protein
DK2814514T3 (en) 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
SG11201406769RA (en) 2012-05-10 2014-11-27 Massachusetts Inst Technology Agents for influenza neutralization
NZ703298A (en) 2012-06-07 2016-04-29 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
ES2712648T3 (es) 2012-06-19 2019-05-14 Ambrx Inc Conjugados de fármaco de anticuerpo anti-CD70
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN103571804B (zh) * 2012-08-10 2015-08-12 中国科学院生物物理研究所 3-吡唑基酪氨酸翻译系统及其应用
EP2887966B1 (en) 2012-08-22 2018-07-18 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Engineered anthrax lethal toxin for targeted delivery
WO2014035364A2 (en) * 2012-08-27 2014-03-06 Empire Technology Development Llc Gelatin alkyd peptides and uses thereof
ES2728864T3 (es) 2012-08-31 2019-10-29 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
CA2885796C (en) 2012-09-24 2022-05-03 Allozyne, Inc. Cell lines
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CN102875733B (zh) * 2012-10-25 2014-06-11 西安科技大学 具有仿细胞外层膜结构的纳米颗粒及其制备方法
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
LT2935320T (lt) 2012-12-18 2019-11-11 Novartis Ag Stabilizuoti insulino tipo augimo faktoriaus polipeptidai
WO2014116730A2 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9255255B2 (en) 2013-03-04 2016-02-09 The Board Of Trustees Of The Leland Stanford Junior University Synthesis of linear and branched polymers of polypeptides through direct conjugation
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
US11156608B2 (en) 2013-03-15 2021-10-26 The Trustees Of The University Of Pennsylvania Method for the site-specific covalent cross-linking of antibodies to surfaces
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6397479B2 (ja) 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US10005838B2 (en) 2013-07-19 2018-06-26 The Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10011649B2 (en) 2013-08-26 2018-07-03 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
MY176976A (en) 2013-10-10 2020-08-28 Bausch Health Ireland Ltd Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
CA2936615C (en) 2014-01-14 2023-06-13 European Molecular Biology Laboratory Multiple cycloaddition reactions for labeling of molecules
US10501734B2 (en) 2014-02-06 2019-12-10 Yale University Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
AU2015259465A1 (en) 2014-05-13 2016-11-17 Bioatla Llc Conditionally active biological proteins
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US10316322B2 (en) 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
US11254933B2 (en) 2014-07-14 2022-02-22 The Regents Of The University Of California CRISPR/Cas transcriptional modulation
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
WO2016073079A2 (en) 2014-09-26 2016-05-12 Yale University Compositions and methods for biocontainment of microorganisms
HUE055311T2 (hu) 2014-10-24 2021-11-29 Bristol Myers Squibb Co Módosított FGF-21 polipeptidek és azok felhasználása
EP4289483A3 (en) 2014-12-04 2024-02-28 Celgene Corporation Biomolecule conjugates
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
SE538541C2 (en) * 2015-01-19 2016-09-13 Fogelstrand Per Method for preparing a biological sample for use in an immunolabeling process
CN107209176B (zh) 2015-01-21 2020-08-14 克罗姆尼贡公司 免疫标记复合物的形成方法及用途
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
AU2016211161C1 (en) 2015-01-30 2023-11-23 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
DK3269809T3 (da) 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
US10483262B2 (en) * 2015-05-15 2019-11-19 Taiwan Semiconductor Manufacturing Co., Ltd. Dual nitride stressor for semiconductor device and method of manufacturing
EP3309250A4 (en) 2015-06-09 2019-06-19 National Institute of Advanced Industrial Science and Technology AMINO ACID MODIFIED NUCLEIC ACID AND USE THEREOF
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
HK1258529A1 (zh) 2015-07-10 2019-11-15 香港科技大学 用於治疗神经退行性和神经炎性病症的方法和组合物
WO2017062334A1 (en) 2015-10-05 2017-04-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
CA3002827A1 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2017196891A1 (en) 2016-05-09 2017-11-16 Biodesy, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques
WO2017204729A1 (en) * 2016-05-25 2017-11-30 Fogelstrand Per Method for preparing a biological sample for use in an immunolabeling process
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
KR102827276B1 (ko) 2016-08-03 2025-07-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3309260A1 (en) 2016-10-14 2018-04-18 European Molecular Biology Laboratory Archaeal pyrrolysyl trna synthetases for orthogonal use
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CA3043667A1 (en) 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
CN110268055A (zh) 2016-12-19 2019-09-20 宽腾矽公司 用于测序反应的聚合酶
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
EP3381932A1 (en) 2017-03-28 2018-10-03 Technische Universität Berlin Modified mussel proteins, uses thereof and related compounds
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
LT3630977T (lt) 2017-06-02 2024-04-25 Ambrx, Inc. Baltymų, kurių sudėtyje yra negamtinių aminorūgščių, gamybos skatinimo būdai ir kompozicijos
KR102744693B1 (ko) 2017-06-09 2024-12-18 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
MA49459A (fr) 2017-06-21 2020-04-29 Amgen Inc Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
CA3069321A1 (en) * 2017-07-11 2019-01-17 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
KR101956042B1 (ko) * 2017-07-13 2019-03-08 서강대학교산학협력단 표적 단백질 내 l-디하이드록시페닐알라닌의 도입 방법
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
AR112969A1 (es) 2017-08-03 2020-01-15 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
KR20200051802A (ko) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
CN111479819B (zh) 2017-12-15 2024-06-14 中外制药株式会社 制备肽的方法和处理碱的方法
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
WO2019213331A1 (en) 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2019237119A1 (en) 2018-06-08 2019-12-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and detection methods for onchocerca volvulus infection
EP3847271A4 (en) * 2018-09-07 2022-10-12 MedImmune, LLC Methods of cell selection
EP4389145A3 (en) 2018-09-11 2024-08-21 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
EP3867265A1 (en) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
CN113056475B (zh) 2018-11-30 2024-09-24 中外制药株式会社 用于肽化合物或酰胺化合物的脱保护方法和在固相反应中的树脂脱除方法以及用于生产肽化合物的方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
EP3696189A1 (en) 2019-02-14 2020-08-19 European Molecular Biology Laboratory Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner
CN113785058B (zh) * 2019-03-04 2024-12-24 得克萨斯A&M大学系统 制作和利用琥珀专性的噬菌体展示文库的方法
US12071396B2 (en) 2019-03-15 2024-08-27 Chugai Seiyaku Kabushiki Kaisha Method for preparing aromatic amino acid derivative
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
US12258304B2 (en) 2019-05-20 2025-03-25 Albert Einstein College Of Medicine Compounds and methods for treatment of bacterial infections
US20220233673A1 (en) 2019-06-04 2022-07-28 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
WO2020247803A2 (en) 2019-06-07 2020-12-10 Massachusetts Institute Of Technology Frameshift suppressor trna compositions and methods of use
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
WO2020264429A1 (en) 2019-06-28 2020-12-30 Quantum-Si Incorporated Polymerizing enzymes for sequencing reactions
EP4041873A4 (en) 2019-10-08 2023-10-25 Trustees of Boston College PROTEINS CONTAINING SEVERAL DIFFERENT UNNATURAL AMINO ACIDS AND METHODS FOR PRODUCING AND USING SUCH PROTEINS
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
TW202128996A (zh) * 2019-10-10 2021-08-01 美商史基普研究協會 用於活體內合成非天然多肽的組合物及方法
WO2021076795A1 (en) * 2019-10-15 2021-04-22 Trustees Of Boston College Chimeric thermostable aminoacyl-trna synthetase for enhanced unnatural amino acid incorporation
US11149280B2 (en) 2019-10-29 2021-10-19 Yale University Engineering organisms resistant to viruses and horizontally transferred genetic elements
SG10202111127YA (en) 2019-11-07 2021-11-29 Chugai Pharmaceutical Co Ltd Cyclic Peptide Compound Having Kras Inhibitory Action
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021138581A1 (en) 2020-01-03 2021-07-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tnap locally administered for promoting periodontal health
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4107258A4 (en) * 2020-02-20 2024-04-17 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MUTANT AMINOACYL-ARNT SYNTHETASES
EP3868882A1 (en) 2020-02-21 2021-08-25 European Molecular Biology Laboratory Archaeal pyrrolysyl trna synthetases for orthogonal use
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
CN111302975A (zh) * 2020-03-30 2020-06-19 滨海吉尔多肽有限公司 一种n-叔丁氧羰基-o-烯丙基-l-酪氨酸的制备方法
EP4139340A1 (en) 2020-04-22 2023-03-01 Merck Sharp & Dohme LLC Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
US12351850B2 (en) 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
JP2023524288A (ja) 2020-05-05 2023-06-09 ジェネンテック， インコーポレイテッド チロシナーゼ媒介部位特異的タンパク質コンジュゲーションのためのシステム及び方法
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
KR20230069187A (ko) * 2020-09-14 2023-05-18 서트로 바이오파마, 인크. 무세포 단백질 합성 시스템을 이용한 항체의 대량 생산 방법
WO2022068920A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
US20230016731A1 (en) * 2021-05-21 2023-01-19 The Regents Of The University Of California Affinity purification sequencing
EP4366782A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
KR20240040134A (ko) 2021-07-09 2024-03-27 브라이트 피크 테라퓨틱스 아게 항체 접합체 및 이의 제조
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
EP4366779A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Modified tnf-antibodies and uses thereof
EP4399283A2 (en) 2021-09-06 2024-07-17 Veraxa Biotech GmbH Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
IL311389A (en) * 2021-09-17 2024-05-01 Absci Corp Transfer RNA composition and use in the production of proteins containing non-standard amino acids
US20240384267A1 (en) 2021-09-20 2024-11-21 The Broad Institute, Inc. Compositions and methods for multiplex decoding of quadruplet codons
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
EP4186529B1 (en) 2021-11-25 2025-07-09 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240105469A (ko) 2021-11-25 2024-07-05 베락사 바이오테크 게엠베하 유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
AU2022404647A1 (en) 2021-12-08 2024-06-13 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
IL314889A (en) 2022-02-23 2024-10-01 Bright Peak Therapeutics Ag IL-18 immunocytokines specific for immune antigens and uses thereof
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CA3259758A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma Inc Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
NL2033185B1 (en) 2022-09-29 2024-04-08 Stichting Vu Compounds for rna stabilisation and delivery
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4656732A1 (en) * 2022-12-31 2025-12-03 Kangma-Healthcode (Shanghai) Biotech Co., Ltd In-vitro cell-free protein synthesis system for inserting non-natural amino acid, and method and use
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
IL322121A (en) 2023-01-16 2025-09-01 Ambrx Inc Anti-CD70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024211306A1 (en) 2023-04-03 2024-10-10 Sutro Biopharma, Inc. Rf1 ko e. coli strains
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
WO2025021929A1 (en) 2023-07-27 2025-01-30 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
US20250197467A1 (en) 2023-08-23 2025-06-19 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025176699A1 (en) 2024-02-20 2025-08-28 LenioBio GmbH A system and method for cell-free unnatural amino acid incorporation
WO2025184315A1 (en) 2024-02-29 2025-09-04 Amgen Inc. Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies
WO2025199030A1 (en) 2024-03-18 2025-09-25 Amgen Inc. Glp-1 receptor agonists and their medical use
EP4644408A1 (en) 2024-04-19 2025-11-05 The Chinese University of Hong Kong Office of Research and Knowledge Transfer Services (ORKTS) Polyethylenimine-modified cry proteins and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537984A (ja) * 2001-04-19 2004-12-24 ザ スクリップス リサーチ インスティテュート 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
DE9115660U1 (de) * 1991-12-18 1992-07-30 Aventis Research & Technologies GmbH & Co KG, 65929 Frankfurt L-Phenylalanyl-tRNA-Synthetase mit erweiterter Substratselektivität aus Mikroorganismen
EP0822990A4 (en) 1995-04-24 2002-07-03 Chromaxome Corp METHODS OF GENERATING AND SCREENING NEW METABOLIC PATHWAYS
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US5756316A (en) 1995-11-02 1998-05-26 Genencor International, Inc. Molecular cloning by multimerization of plasmids
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US5783431A (en) 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
DE10151556A1 (de) * 2001-10-23 2003-04-30 Bosch Gmbh Robert Vorrichtung zum Öffnen und Schließen eines beweglichen Teils
ITTO20020441A1 (it) * 2002-05-24 2003-11-24 Telecom Italia Lab Spa Metodo per determinare l'installazione di costo minimo per le apparecchiature di una rete fissa di telecomunicazione.
ATE526414T1 (de) 2002-10-16 2011-10-15 Scripps Research Inst Ortsspezifische einbindung von ketoaminosäuren in proteine
KR20050073559A (ko) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
US7642085B2 (en) 2002-12-22 2010-01-05 The Scripps Research Institute Protein arrays
KR101171397B1 (ko) 2003-04-17 2012-08-07 더 스크립스 리서치 인스티튜트 진핵 유전자 코드의 확장
CA2527877A1 (en) 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
ATE386133T1 (de) 2003-07-07 2008-03-15 Scripps Research Inst Zusammensetzungen der orthogonalen lysyl-trna und aminoacyl-trna synthetase paaren und ihre verwendungen
US7527943B2 (en) 2003-07-07 2009-05-05 The Scripps Research Institute Compositions of orthogonal glutamyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
BRPI0415308A (pt) 2003-10-14 2006-12-05 Scripps Research Inst incorporação especìfica de local de aminoácidos redox ativos em proteìnas
US7741071B2 (en) 2003-12-18 2010-06-22 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
US7399619B2 (en) 2004-05-25 2008-07-15 The Scripps Research Institute Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for structure determination
BRPI0515547A (pt) 2004-09-21 2008-07-29 Scripps Research Inst incorporação in vivo de aminoácidos alquinil em proteìnas em eubacterias
WO2006034410A2 (en) 2004-09-21 2006-03-30 The Scripps Resarch Institute Adding photoregulated amino acids to the genetic code
US20060110784A1 (en) 2004-09-22 2006-05-25 The Scripps Research Institute Site-specific labeling of proteins for NMR studies
WO2006045116A2 (en) 2004-10-20 2006-04-27 The Scripps Research Institute In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
WO2006110182A2 (en) 2004-10-27 2006-10-19 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
FR2888097B1 (fr) * 2005-07-06 2007-10-05 Oreal Dispositif de conditionnement et d'application comportant un organe d'essorage
BRPI0617191A2 (pt) 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos
EP1991680B1 (en) 2006-03-09 2013-08-21 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
US7790847B2 (en) 2006-03-16 2010-09-07 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
CA2652894A1 (en) 2006-05-23 2007-12-06 The Scripps Research Institute Genetically encoded fluorescent coumarin amino acids
US7421795B2 (en) * 2006-08-04 2008-09-09 Seagate Technology Llc Sapphire alignment fixture
WO2008036392A2 (en) 2006-09-21 2008-03-27 The Scripps Research Institute Genetically programmed expression of selectively sulfated proteins in eubacteria
RU2009112104A (ru) 2006-10-18 2010-11-27 Зе Скрипс Ресеч Инститьют (Us) Генетическое встраивание не встречающихся в природе аминокислот в белки клеток млекопитающих
TWI334126B (en) * 2007-07-17 2010-12-01 Au Optronics Corp Voltage adjusting circuit, method, and display apparatus having the same
JP4978419B2 (ja) * 2007-10-23 2012-07-18 富士ゼロックス株式会社 光送受信モジュール
MX2010004464A (es) 2007-10-25 2010-06-07 Scripps Research Inst Incorporacion genetica de 3-aminotirosina a reductasas.
US9249408B2 (en) 2007-11-02 2016-02-02 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
US20090148887A1 (en) 2007-11-02 2009-06-11 The Scripps Research Institute Genetically encoded boronate amino acid
WO2009064416A2 (en) 2007-11-15 2009-05-22 The Scripps Research Institute Genetic incorporation of an alpha-hydroxy acid into proteins to generate ester backbone linkages at defined sites
US8218509B2 (en) * 2008-01-15 2012-07-10 Apple Inc. Dynamic allocation of communication resources in a wireless system
US8318172B2 (en) 2008-02-08 2012-11-27 The Scripps Research Institute Breaking immunological tolerance with a genetically encoded unnatural amino acid
WO2009151491A2 (en) 2008-02-27 2009-12-17 The Scripps Research Institute In vivo incorporation of an unnatural amino acid comprising a 1,2-aminothiol group
US8609383B2 (en) 2008-12-10 2013-12-17 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
US20090197339A1 (en) 2008-12-10 2009-08-06 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris
WO2010114615A2 (en) 2009-04-03 2010-10-07 The Scripps Research Institute A facile system for encoding unnatural amino acids in mammalian cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537984A (ja) * 2001-04-19 2004-12-24 ザ スクリップス リサーチ インスティテュート 直交ｔＲＮＡ−アミノアシルｔＲＮＡシンテターゼ対を生産するための方法及び組成物
JP2009132704A (ja) * 2001-04-19 2009-06-18 Scripps Res Inst:The 非天然アミノ酸のインビボ組込み

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009132704A (ja) * 2001-04-19 2009-06-18 Scripps Res Inst:The 非天然アミノ酸のインビボ組込み
JP2010502218A (ja) * 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
JP2010502222A (ja) * 2006-09-08 2010-01-28 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP2010504096A (ja) * 2006-09-21 2010-02-12 ザ スクリップス リサーチ インスティテュート 真正細菌における選択的に硫酸化された蛋白質の遺伝的にプログラムされた発現
JP2011502507A (ja) * 2007-11-02 2011-01-27 ザ スクリプス リサーチ インスティチュート 非天然アミノ酸を含有する蛋白質を使用する指向的進化
JP2011527886A (ja) * 2007-12-11 2011-11-10 ザ スクリプス リサーチ インスティチュート メタノール資化性酵母ピキア・パストリスにおけるインビボ非天然アミノ酸発現
WO2011158895A1 (ja) * 2010-06-16 2011-12-22 独立行政法人理化学研究所 非天然タンパク質製造用の組換え細菌の作製方法、及びその利用
JP5858543B2 (ja) * 2010-06-16 2016-02-10 国立研究開発法人理化学研究所 非天然タンパク質製造用の組換え細菌の作製方法、及びその利用
US9340790B2 (en) 2010-06-16 2016-05-17 Riken Method for constructing recombinant bacterium for producing non-native protein, and utilization of same
KR101568336B1 (ko) 2013-07-02 2015-11-12 서강대학교산학협력단 목적 단백질의 돌연변이체를 생성하는 세포, 상기 세포의 제조 방법, 및 상기 세포를 이용한 목적 단백질의 돌연변이체의 제조 방법
JP2022554396A (ja) * 2019-11-05 2022-12-28 ニトロ バイオサイエンシーズ， インコーポレイテッド パラ－ニトロ－ｌ－フェニルアラニンの生合成

Also Published As

Publication number Publication date
US7638300B2 (en) 2009-12-29
JP5766925B2 (ja) 2015-08-19
JP6239888B2 (ja) 2017-11-29
DK1490483T3 (en) 2015-09-07
IL196714A (en) 2013-10-31
IL187588A (en) 2011-11-30
US7713721B2 (en) 2010-05-11
DK1456360T3 (en) 2015-08-31
US7045337B2 (en) 2006-05-16
CA2444098C (en) 2016-06-21
US20130309720A1 (en) 2013-11-21
CA2443757C (en) 2016-09-27
IL158419A0 (en) 2004-05-12
IL196762A (en) 2015-03-31
US20030082575A1 (en) 2003-05-01
JP2011030571A (ja) 2011-02-17
MXPA03009566A (es) 2004-12-06
US20080227152A1 (en) 2008-09-18
US20060233744A1 (en) 2006-10-19
US20060234367A1 (en) 2006-10-19
EP2796546A1 (en) 2014-10-29
US20110027867A1 (en) 2011-02-03
ES2464532T3 (es) 2014-06-03
US20090053791A1 (en) 2009-02-26
US20030108885A1 (en) 2003-06-12
US7368275B2 (en) 2008-05-06
US20090227002A1 (en) 2009-09-10
US20080261311A1 (en) 2008-10-23
WO2002086075A3 (en) 2004-06-24
EP1490483A4 (en) 2007-02-07
IL196714A0 (en) 2009-11-18
CA2444098A1 (en) 2002-10-31
CA2443757A1 (en) 2002-10-31
JP2016112021A (ja) 2016-06-23
US7083970B2 (en) 2006-08-01
EP1456360B1 (en) 2015-06-03
US8114648B2 (en) 2012-02-14
DK2322631T3 (en) 2015-01-12
EP1490483A2 (en) 2004-12-29
US20080167243A1 (en) 2008-07-10
HK1203558A1 (en) 2015-10-30
JP2009077731A (ja) 2009-04-16
EP2128246B1 (en) 2014-03-12
US20120101006A1 (en) 2012-04-26
US20060063244A1 (en) 2006-03-23
JP2009132704A (ja) 2009-06-18
JP2013255502A (ja) 2013-12-26
EP1456360A2 (en) 2004-09-15
US7915025B2 (en) 2011-03-29
WO2002085923A3 (en) 2004-05-27
US8183012B2 (en) 2012-05-22
JP6294368B2 (ja) 2018-03-14
EP1490483B1 (en) 2015-06-03
WO2002085923A2 (en) 2002-10-31
AU2002303431B2 (en) 2007-10-04
HK1065065A1 (en) 2005-02-08
US20120202243A1 (en) 2012-08-09
US8012739B2 (en) 2011-09-06
DK2128246T3 (da) 2014-05-12
US20070117184A1 (en) 2007-05-24
US20080166783A1 (en) 2008-07-10
US8173364B2 (en) 2012-05-08
HK1069848A1 (en) 2005-06-03
US9163271B2 (en) 2015-10-20
IL196762A0 (en) 2011-07-31
MXPA03009563A (es) 2004-12-06
IL158418A0 (en) 2004-05-12
EP2322631A1 (en) 2011-05-18
US20050208536A1 (en) 2005-09-22
WO2002086075A2 (en) 2002-10-31
US7354761B2 (en) 2008-04-08
AU2002256292C1 (en) 2008-08-14
EP2796546B1 (en) 2017-08-09
JP2004537984A (ja) 2004-12-24
EP2322631B1 (en) 2014-11-12
AU2002256292B2 (en) 2007-12-06
HK1158259A1 (en) 2012-07-13
AU2002303431C1 (en) 2008-03-06
US8173392B2 (en) 2012-05-08
IL158419A (en) 2013-05-30
IL187775A0 (en) 2011-08-01
US20050250183A1 (en) 2005-11-10
US8030074B2 (en) 2011-10-04
US20090068717A1 (en) 2009-03-12
EP2128246A1 (en) 2009-12-02
EP1456360A4 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
DK1490483T3 (en) In vivo incorporation of unnatural amino acids
AU2002256292A1 (en) In vivo incorporation of unnatural amino acids
AU2008200780B2 (en) In vivo incorporation of unnatural amino acids
HK1158259B (en) Methods and compositions for the production of orthogonal trna-aminoacyl-trna synthetase pairs
HK1069848B (en) In vivo incorporation of unnatural amino acids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081113

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090803

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100810

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110802

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111028

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120801

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120801